Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. (not Decoy Therapeutics Inc.) on February 23, 2015. The filing discloses the election of a new director and details historical agreements with the company's founders regarding intellectual property, equity, and compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and contractual obligations rather than financial performance.
- Director Compensation: Roderick MacKinnon, M.D., will receive cash compensation consistent with other non-employee directors.
- Scientific Advisory Board Retainer: Dr. MacKinnon receives an annual retainer of $90,000 (increased from $60,000), payable quarterly.
- Historical Reimbursement: The company agreed to reimburse founders up to an aggregate of $70,000 for patent costs incurred prior to 2014.
- Equity Grants: Dr. MacKinnon holds 416,978 shares of Common Stock (subject to vesting) and 56,041 stock options.
Material Changes and Agreements
The primary material change is the election of Roderick MacKinnon, M.D. to the Board of Directors to fill a vacancy. He is designated as a Class I member serving until the 2016 annual meeting. The filing also reiterates the terms of several foundational agreements:
- Royalty Agreement: The company is obligated to pay founders a perpetual royalty of 2% of gross sales for products treating neuromuscular disorders using the company's intellectual property.
- Founders Agreement: Originally adopted in 2014, this agreement was terminated in its entirety on April 10, 2014, except for anti-dilution protections and miscellaneous provisions.
- Technology Assignment: Founders assigned all relevant technology and intellectual property rights to the company.
Outlook, Risks, and Contingencies
The filing does not provide specific guidance or outlook on future financial performance. However, it highlights the following contingencies and risks:
- Indemnification Liability: The company has entered into a standard Indemnity Agreement with Dr. MacKinnon, potentially requiring the company to cover legal expenses, judgments, fines, and settlement amounts arising from his service as a director.
- Perpetual Royalty Obligation: The 2% royalty on gross sales is perpetual, representing a long-term contingent liability tied to future product sales.
- Equity Vesting: Significant portions of founder equity are subject to vesting schedules tied to continuous service.
Investor Verification Checklist
- Verify the exact cash compensation amount for non-employee directors as detailed in the final prospectus dated January 28, 2015.
- Confirm the current status of the 2% perpetual royalty agreement and any potential future product sales triggering this obligation.
- Review the vesting schedules and acceleration provisions for Dr. MacKinnon's 416,978 shares and 56,041 stock options.
- Assess the potential financial impact of the indemnification agreement in the event of legal proceedings against the new director.